Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.
Keywords: Akkermansia; Diabetes mellitus, type 2; Lipopolysaccharides; Obesity; Peptidoglycan.
Copyright © 2021 The Korean Society of Lipid and Atherosclerosis.